TecDara shows strong myeloma control, but early infection risk demands vigilant prophylaxis; safety improves after six months, supporting second-line use.
Luciano J. Costa, MD, PhD, is a professor of medicine in the Division of Hematology and Oncology at the University of Alabama at Birmingham, where his research focuses on multiple myeloma, including MRD-adapted and bispecific antibody-based treatment strategies. He is a lead investigator of the MASTER trial and a co-investigator on MajesTEC-3, the phase 3 study evaluating teclistamab plus daratumumab in relapsed/refractory multiple myeloma.
A new post hoc analysis of the phase 3 MajesTEC-3 trial answers a question that has followed teclistamab plus daratumumab (Tec-Dara) since its survival curves first crossed a control arm early in follow-up: does the regimen's efficacy edge come at the cost of added fatal toxicity? Luciano J. Costa, MD, PhD, of the University of Alabama at Birmingham, walks through the answer—no. By separating non-relapse mortality from progression-driven death, the analysis shows Tec-Dara's survival advantage over daratumumab-based triplets is driven almost entirely by a steep drop in disease progression, with non-relapse mortality essentially unchanged between arms (10.2% vs 9.0% at 36 months).
Costa explains why the survival curves intersect around month 10 before separating sharply in Tec-Dara's favor—a 78% reduction in the hazard of death beyond that point—and what it means for how pharmacists counsel patients through the early, infection-heavy weeks of treatment. He makes the case for universal immunoglobulin replacement and infection prophylaxis as the single most important safety intervention clinicians control, describes how risk drops once patients reach monthly maintenance dosing, and argues the data support Tec-Dara as a new standard of care as early as second-line relapsed/refractory multiple myeloma.
